DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Claritin (Loratadine) - Side Effects and Adverse Reactions




Approximately 90,000 patients, aged 12 and older, received loratadine tablets 10 mg once daily in controlled and uncontrolled studies. Placebo-controlled clinical trials at the recommended dose of 10 mg once a day varied from 2 weeks' to 6 months' duration. The rate of premature withdrawal from these trials was approximately 2% in both the treated and placebo groups.

Percent of Patients Reporting
10 mg q.d. 1 mg bid 60 mg bid
n=1926 n=2545 n=536 n=684
Headache 12 11 8 8
Somnolence 8 6 22 9
Fatigue 4 3 10 2
Dry Mouth 3 2 4 3

Adverse events reported in placebo-controlled chronic idiopathic urticaria trials were similar to those reported in allergic rhinitis studies.
Adverse event rates did not appear to differ significantly based on age, sex, or race, although the number of nonwhite subjects was relatively small.

CLARITIN REDITABS (loratadine rapidly-disintegrating tablets): Approximately 500 patients received loratadine rapidly-disintegrating tablets in controlled clinical trials of 2 weeks' duration. In these studies, adverse events were similar in type and frequency to those seen with loratadine tablets and placebo.
Administration of loratadine rapidly-disintegrating tablets did not result in an increased reporting frequency of mouth or tongue irritation.

CLARITIN Syrup: Approximately 300 pediatric patients 6 to 12 years of age received 10 mg loratadine once daily in controlled clinical trials for a period of 8 to 15 days. Among these, 188 children were treated with 10 mg loratadine syrup once daily in placebo-controlled trials. Adverse events in these pediatric patients were observed to occur with type and frequency similar to those seen in the adult population. The rate of premature discontinuance due to adverse events among pediatric patients receiving loratadine 10 mg daily was less than 1%.

Adverse Events Occurring with a Frequency of ≥2% in Loratadine Syrup-Treated Patients (6-12 Years Old) in Placebo-Controlled Trials, and More Frequently Than in the Placebo Group
Percent of Patients Reporting
Loratadine Placebo Chlorpheniramine
10 mg q.d. 2-4 mg bid/tid
n=188 n=262 n=170
Nervousness 4 2 2
Wheezing 4 2 5
Fatigue 3 2 5
Hyperkinesia 3 1 1
Abdominal Pain 2
Conjunctivitis 2 <1 1
Dysphonia 2 <1
Malaise 2 1
Upper Respiratory Tract Infection 2 <1

Sixty pediatric patients 2 to 5 years of age received 5 mg loratadine once daily in a double-blind, placebo-controlled clinical trial for a period of 14 days. No unexpected adverse events were seen given the known safety profile of loratadine and likely adverse reactions for this patient population. The following adverse events occurred with a frequency of 2 to 3 percent in the loratadine syrup-treated patients (2 to 5 years old) during the placebo-controlled trial, and more frequently than in the placebo group: diarrhea, epistaxis, pharyngitis, influenza-like symptoms, fatigue, stomatitis, tooth disorder, earache, viral infection, and rash.
In addition to those adverse events reported above (≥2%), the following adverse events have been reported in at least one patient in loratadine clinical trials in adult and pediatric patients.

Autonomic Nervous System: Altered lacrimation, altered salivation, flushing, hypoesthesia, impotence, increased sweating, thirst.

Body as a Whole: Angioneurotic edema, asthenia, back pain, blurred vision, chest pain, earache, eye pain, fever, leg cramps, malaise, rigors, tinnitus, viral infection, weight gain.

Cardiovascular System: Hypertension, hypotension, palpitations, supraventricular tachyarrhythmias, syncope, tachycardia.

Central and Peripheral Nervous System: Blepharospasm, dizziness, dysphonia, hypertonia, migraine, paresthesia, tremor, vertigo.

Gastrointestinal System: Altered taste, anorexia, constipation, diarrhea, dyspepsia, flatulence, gastritis, hiccup, increased appetite, nausea, stomatitis, toothache, vomiting.

Musculoskeletal System: Arthralgia, myalgia.

Psychiatric: Agitation, amnesia, anxiety, confusion, decreased libido, depression, impaired concentration, insomnia, irritability, paroniria.

Reproductive System: Breast pain, dysmenorrhea, menorrhagia, vaginitis.

Respiratory System: Bronchitis, bronchospasm, coughing, dyspnea, epistaxis, hemoptysis, laryngitis, nasal dryness, pharyngitis, sinusitis, sneezing.

Skin and Appendages: Dermatitis, dry hair, dry skin, photosensitivity reaction, pruritus, purpura, rash, urticaria.

Urinary System: Altered micturition, urinary discoloration, urinary incontinence, urinary retention.

In addition, the following spontaneous adverse events have been reported rarely during the marketing of loratadine: abnormal hepatic function, including jaundice, hepatitis, and hepatic necrosis; alopecia; anaphylaxis; breast enlargement; erythema multiforme; peripheral edema; and seizures.


Loratadine (10 mg once daily) has been coadministered with therapeutic doses of erythromycin, cimetidine, and ketoconazole in controlled clinical pharmacology studies in adult volunteers. Although increased plasma concentrations (AUC 0-24 hrs) of loratadine and/or descarboethoxyloratadine were observed following coadministration of loratadine with each of these drugs in normal volunteers (n = 24 in each study), there were no clinically relevant changes in the safety profile of loratadine, as assessed by electrocardiographic parameters, clinical laboratory tests, vital signs, and adverse events. There were no significant effects on QTc intervals, and no reports of sedation or syncope. No effects on plasma concentrations of cimetidine or ketoconazole were observed. Plasma concentrations (AUC 0-24 hrs) of erythromycin decreased 15% with coadministration of loratadine relative to that observed with erythromycin alone. The clinical relevance of this difference is unknown. These above findings are summarized in TABLE 1.

Effects on Plasma Concentrations (AUC 0-24 hrs) of Loratadine and Descarboethoxyloratadine After 10 Days of Coadministration (Loratadine 10 mg) in Normal Volunteers
Loratadine Descarboethoxyloratadine
Erythromycin (500 mg q8h) +40% +46%
Cimetidine (300 mg qid) +103% +6%
Ketoconazole (200 mg q12h) +307% +73%

There does not appear to be an increase in adverse events in subjects who received oral contraceptives and loratadine.


Below is a sample of reports where side effects / adverse reactions may be related to Claritin. The information is not vetted and should not be considered as verified clinical evidence.

Possible Claritin side effects / adverse reactions in 49 year old female

Reported by a individual with unspecified qualification from Canada on 2011-10-11

Patient: 49 year old female weighing 76.0 kg (167.2 pounds)

Reactions: Hypersensitivity, Skin Exfoliation, Drug Hypersensitivity, Chills, Pain, Urticaria, Skin Oedema, Erythema, Convulsion, Skin Warm

Adverse event resulted in: life threatening event, hospitalization

Suspect drug(s):

Possible Claritin side effects / adverse reactions in 42 year old female

Reported by a consumer/non-health professional from United States on 2011-10-12

Patient: 42 year old female

Reactions: Pharyngeal Oedema, Pain in Extremity, Pain, Oedema Peripheral, Urticaria

Suspect drug(s):

Other drugs received by patient: Prednisone

Possible Claritin side effects / adverse reactions in 44 year old female

Reported by a physician from Canada on 2011-10-14

Patient: 44 year old female

Reactions: Thrombolysis, Hypotension, Bradycardia, Electrocardiogram ST Segment Elevation, Acute Myocardial Infarction

Adverse event resulted in: hospitalization

Suspect drug(s):

See index of all Claritin side effect reports >>

Drug label data at the top of this Page last updated: 2006-02-14

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017